Lowest Price Guaranteed From USD 5,899
Published
April 2021
Pages
250
View Count
6128
-thumb.PNG) |
 |
-thumb.PNG) |
 |
-thumb.PNG) |
-thumb.PNG) |
-thumb.PNG) |
-thumb.PNG) |
 |
Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions. The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favorable safety profiles. Since 2017, over 10 peptide-based drugs have received marketing approvals across different regions of the world. Examples of recently approved peptide drugs include (in the reverse chronological order of approval) Lupkynis™ (2021), Mycappsa® (2020), Scenesse® (2019), Rybelsus® (2019) and Vyleesi® (2019). Further, more than 150 therapeutic peptides are currently under clinical investigation, while several novel leads are being evaluated in the early stages of research. In this context, it is also worth mentioning that peptide-based therapy products account for 5% of the global pharmaceutical revenues generated annually.
Presently, several drug developers, along with technology providers, are actively engaged in the development of novel peptide therapeutics, such as peptide drug conjugates and cell penetrating peptides. Innovation in this field of research is mostly focused on improving drug delivery methods, API stability, target affinity, and optimizing toxicity profiles. Several big pharma players have also demonstrated interest in peptide therapeutics and are investing both time and capital in this domain. Since 2019, more than USD 3 billion has been invested into companies that are involved in the development of various types of peptide drugs. In addition, the market is witnessing significant partnership activity; several licensing agreements, focused on drug development and commercialization, were recently inked between stakeholders in this industry.
The “Peptide Therapeutics Market by Type of Peptide (Small, Medium and Large), Route of Administration (Intravenous, Oral, Subcutaneous, Topical and Others), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World) and Key Therapeutic Area (Metabolic Diseases, Oncological Diseases, Endocrine Diseases, Digestive and Gastrointestinal Diseases and Others): Industry Trends and Global Forecasts, 2021 – 2030” report features an extensive study of the current market landscape of peptide therapeutics. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:
One of the key objectives of the report was to estimate the existing market size and future opportunity associated with peptide therapeutics, over the next decade. Based on the sales for approved peptide drugs, during the period 2015-2020, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of peptide (small, medium and large), [B] route of administration (intravenous, oral, subcutaneous, topical and others), [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and [D] key therapeutic area (metabolic diseases, oncological diseases, endocrine diseases, digestive and gastrointestinal diseases and others). In addition, the report provides value creation analysis of approved and clinical peptide-based therapies across different therapeutic areas.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the peptide therapeutics market and its likely evolution in the short to mid term and long term.
Chapter 3 provides a general overview of peptide therapeutics, including a discussion on their structure, classification and types of modifications. In addition, the chapter includes information on the historical evolution of peptides. Further, it features a brief overview of the design and development of therapeutic peptides, as well as a comparison between traditional and novel peptide technologies, along with the advantages and disadvantages associated with peptide-based therapies. Furthermore, the chapter presents details on the applications of peptide drugs along with providing an overview of the upcoming future trends, which, we believe, are likely to influence the growth of the peptide therapeutics market.
Chapter 4 includes information on over 300 peptide-based therapies that are currently approved or are in different stages of development. It features a detailed analysis of pipeline molecules, based on several relevant parameters, such as phase of development (marketed, clinical, preclinical and discovery), type of peptide (small, medium and large), number of amino acids, route of administration (intravenous, oral, subcutaneous, topical and others) and key therapeutic area. Further, we have presented a grid analysis of peptide therapeutics based on phase of development, route of administration and key therapeutic area.
Chapter 5 provides a detailed review of the players engaged in the development of peptide drugs, along with information on their year of establishment, company size, location of headquarters. Further, we have presented a logo landscape of peptide developers in North America, Europe and the Asia-Pacific region on the basis of phase of development and key players engaged in this domain. In addition, we have presented a heat map analysis of developers on the basis of company size, phase of development and geography.
Chapter 6 provides detailed profiles of prominent players engaged in development of peptide drugs. Each company profile features a brief overview of the company, financial details / information (if available), pipeline details, recent developments and an informed future outlook.
Chapter 7 highlights top big biopharma players engaged in the field of therapeutic peptides, featuring a heat map analysis based on several parameters, including number of amino acids, route of administration and therapeutic area.
Chapter 8 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players since 2015. It includes a brief description on the various types of partnership models (which include acquisition-based agreements, clinical trial agreements, distribution agreements, joint ventures, licensing agreements, manufacturing agreements, product-based agreements, R&D agreements and services agreements) that have been adopted by stakeholders in this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the peptide therapeutics. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.
Chapter 9 presents details on various funding instances, investments and grants reported within the peptide therapeutics domain. The chapter includes information on various types of investments (such as venture capital financing, debt financing, grants, capital raised from IPO and subsequent offerings) received by the companies between 2015 and 2021, highlighting the growing interest of the venture capital community and other strategic investors in this market.
Chapter 10 provides a detailed analysis of completed, ongoing, and planned clinical studies of various therapeutic peptides, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target therapeutic area, and key geographical regions.
Chapter 11 features an analysis of the clinical and commercial attractiveness of the peptide drugs designed for the treatment of various types of diseases. In the chapter, each of the drugs / drug candidates were plotted on a 2X2 matrix, with clinical attractiveness (abscissa) and commercial attractiveness (ordinate) as the two axes. The clinical attractiveness of a drug was determined based on the sample size of the associated trial, route of administration, therapy type and dosing frequency. The commercial attractiveness of a drug was determined based on the size of target patient population, expected launch date and company size of the developer company.
Chapter 12 is a case study focused on the role of service providers that operate within the peptide therapeutics market and captures information on the various CROs, CMOs and custom peptide manufacturers that are actively involved in this segment of the peptide therapeutics market. In addition, the chapter includes the advantages and challenges associated with outsourcing, along with the key parameters that need to be considered while selecting a service provider.
Chapter 13 is a case study presenting the key characteristics of novel peptides drugs, along with information on the applications, advantages and key challenges involved in their development processes.
Chapter 14 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2030. It also includes future sales projections of peptide-based therapies that are either marketed or in advanced stages of clinical development (phase II/III and above). The chapter also presents a detailed market segmentation on the basis of [A] type of peptide (small, medium and large), [B] route of administration (intravenous, oral, subcutaneous, topical and others), and [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and [D] key therapeutic area (metabolic diseases, oncological diseases, endocrine diseases, digestive and gastrointestinal diseases and others). In addition, the report provides value creation analysis of approved and clinical peptide-based therapies across different therapeutic areas.
Chapter 15 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the peptide therapeutics market, based on the research and analysis described in the previous chapters.
Chapter 16 is an appendix that provides the list of approved peptide therapeutics during the period 2000 and 2012.
Chapter 17 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3 INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Peptides
3.3. Classification of Peptides
3.4. Modification of Peptides
3.4.1. N-Terminal Modifications
3.4.2. Internal Modifications
3.4.3. C-Terminal Modifications
3.4.4. Other Modifications
3.5. Evolution of Peptide Therapeutics
3.6. Design and Development of Peptide Therapeutics
3.6.1. Traditional versus Novel Peptide Technologies
3.7. Advantages and Disadvantages of Peptide Therapeutics
3.8. Applications of Peptide Therapeutics
3.9. Future Perspectives
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Peptide Therapeutics: Overall Market Overview
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Peptide
4.2.3. Analysis by Route of Administration
4.2.4. Analysis by Phase of Development and Route of Administration
4.2.5. Analysis by Therapeutic Area
4.2.6. Analysis by Phase of Development and Therapeutic Area
4.2.7. Analysis by Route of Administration and Therapeutic Area
4.2.8. Analysis by Phase of Development, Route of Administration and Therapeutic
5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Peptide Therapeutics: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Phase of Development and Geography (Logo Landscape)
5.2.4. Key Players: Analysis by Number of Product Candidates
5.3. Analysis by Company Size, Phase of Development and Geography (Heat Map
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Apellis Pharmaceuticals
6.2.1 Company Overview
6.2.2. Financial Information
6.2.3 Pipeline Details
6.2.4. Recent Developments and Future Outlook
6.3. BioLineRx
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Pipeline Details
6.3.4. Recent Developments and Future Outlook
6.4. Eli Lilly
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Details
6.4.4. Recent Developments and Future Outlook
6.5. FirstString Research
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Pipeline Details
6.5.4. Recent Developments and Future Outlook
6.6. Novo Nordisk
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Details
6.6.4. Recent Developments and Future Outlook
6.7. Palatin Technologies
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Details
6.7.4. Recent Developments and Future Outlook
6.8. RegeneRx Biopharmaceuticals
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Pipeline Details
6.8.4. Recent Developments and Future Outlook
6.9. Stealth BioTherapeutics
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Pipeline Details
6.9.4. Recent Developments and Future Outlook
6.10. Takeda
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Pipeline Details
6.10.4. Recent Developments and Future Outlook
6.11. Zealand Pharma
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Pipeline Details
6.11.4. Recent Developments and Future Outlook
7. PEPTIDE THERAPEUTICS FOCUSED INITIATIVES OF BIG PHARMA
7.1. Chapter Overview
7.2. Top Pharmaceutical Companies: Peptide Therapeutics Focused Initiatives
7.2.1. Analysis by Number of Amino Acids
7.2.2. Analysis by Route of Administration
7.2.3. Analysis by Therapeutic Area
7.3. Benchmark Analysis of Key Parameters
7.3.1. Spider Web Analysis: Pipeline Strength
7.3.2. Spider Web Analysis: Partnerships
7.3.3. Spider Web Analysis: Investments
7.3.4. Spider Web Analysis: Clinical Trials
7.4. Benchmark Analysis of Big Pharmaceutical Players
7.4.1. Spider Web Analysis: Novo Nordisk
7.4.2. Spider Web Analysis: Amgen
7.4.3. Spider Web Analysis: Takeda
7.4.4. Spider Web Analysis: Eli Lilly
7.4.5. Spider Web Analysis: Johnson and Johnson
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Peptide Therapeutics: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Peptide
8.3.5. Analysis by Route of Administration
8.3.6. Analysis by Type of Partnership and Route of Administration
8.3.7. Analysis by Type of Partnership, Type of Peptide and Route of Administration
8.3.8. Analysis by Phase of Development
8.3.9. Analysis by Type of Partnership and Phase of Development
8.3.10. Analysis by Therapeutic Area
8.3.11. Analysis by Year, Type of Partnership and Therapeutic Area (Grid
8.4. Most Active Players: Analysis by Number of Partnerships
8.5. Regional Analysis
8.5.1. Intracontinental and Intercontinental Agreements
8.5.2. Local and International Agreements
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Peptide Therapeutics: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Year and Type of Funding
9.3.5. Analysis of Amount Invested by Geography
9.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount
9.3.7. Key Investors: Analysis by Number of Funding Instances
9.3.8. Analysis by Phase of Development
9.3.9. Analysis by Therapeutic Area
10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Peptide Therapeutics: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Trial Recruitment Status
10.3.5. Analysis by Trial Registration Year and Enrolled Patient Population
10.3.6. Analysis by Study Design
10.3.7. Analysis by Type of Sponsor / Collaborator
10.3.8. Most Active Players: Analysis by Number of Registered Trials
10.3.9. Emerging Focus Area
10.3.10. Analysis by Therapeutic Area
10.3.11. Geographical Analysis by Number of Registered Trials
10.3.12. Geographical Analysis by Enrolled Patient Population
11. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.2.1. Assumptions and Key Parameters
11.3. Affiliated Insights
11.3.1. Clinical and Commercial Attractiveness Analysis: Autoimmune Diseases
11.3.2. Clinical and Commercial Attractiveness Analysis: Cardiovascular Diseases
11.3.3. Clinical and Commercial Attractiveness Analysis: Central Nervous System
11.3.4. Clinical and Commercial Attractiveness Analysis: Digestive and Gastrointestinal
11.3.5. Clinical and Commercial Attractiveness Analysis: Endocrine Diseases
11.3.6. Clinical and Commercial Attractiveness Analysis: Genetic Diseases
11.3.7. Clinical and Commercial Attractiveness Analysis: Hematological Diseases
11.3.8. Clinical and Commercial Attractiveness Analysis: Infectious Diseases
11.3.9. Clinical and Commercial Attractiveness Analysis: Inflammatory Diseases
11.3.10. Clinical and Commercial Attractiveness Analysis: Metabolic Diseases
11.3.11. Clinical and Commercial Attractiveness Analysis: Oncological Diseases
11.3.12. Clinical and Commercial Attractiveness Analysis: Ophthalmic Diseases
11.3.13. Clinical and Commercial Attractiveness Analysis: Other Diseases
12. CASE STUDY: CONTRACT SERVICES LANDSCAPE
12.1.1. Chapter Overview
12.2. Role of Service Providers
12.2.1. List of Peptide CROs
12.2.2. List of Platform Providers
12.2.3. List of Peptide CMOs
12.2.3.1. List of Custom Peptide Manufacturers
12.3. Advantages of Outsourcing
12.4. Risks and Challenges Associated with Outsourcing
13. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS
13.1. Chapter Overview
13.2. Overview of Novel Peptide Therapeutics
13.3. Advantages and Applications of Novel Peptide Therapeutics
13.4. Key Challenges Associated with Novel Peptide Therapeutics
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global Peptide Therapeutics Market, 2021-2030
14.4.1. Global Peptide Therapeutics Market, 2021-2030: Distribution by Type of Peptide
14.4.2. Peptide Therapeutics Market, 2021-2030: Distribution by Number of Amino
14.4.3. Peptide Therapeutics Market, 2021-2030: Distribution by Route of
14.4.4. Peptide Therapeutics Market, 2021-2030: Distribution by Geography
14.4.5. Peptide Therapeutics Market, 2021-2030: Distribution by Key Therapeutic Area
14.5. Autoimmune Diseases
14.5.1. Value Creation Analysis
14.5.2. Sales Forecast for Approved Peptide Therapeutics
14.5.2.1. Tymlos ®
14.5.3. Sales Forecast for Clinical Peptide Therapeutics
14.5.3.1. Ampion / DMI 9523
14.5.3.2. TBRIA
14.6. Cardiovascular Diseases
14.6.1. Value Creation Analysis
14.6.2. Sales Forecast for Clinical Peptide Therapeutics
14.6.2.1. Giapreza ®
14.6.2.2. Kalbitor ®
14.6.3. Sales Forecast for Clinical Peptide Therapeutics
14.6.3.1. Elamipretide / MTP-131
14.6.3.2. Nerinetide
14.7. CNS Diseases
14.7.1. Value Creation Analysis
14.7.2. Sales Forecast for Clinical Peptide Therapeutics
14.7.2.1. Rybelsus ®
14.8. Dermatological Diseases
14.8.1. Value Creation Analysis
14.8.2. Sales Forecast for Approved Peptide Therapeutics
14.8.2.1. Melgain
14.9. Digestive and Gastrointestinal Diseases
14.9.1. Value Creation Analysis
14.9.2. Sales Forecast for Approved Peptide Therapeutics
14.9.2.1. Gattex ®
14.9.2.2. Trulance ®
14.9.3. Sales Forecast for Clinical Peptide Therapeutics
14.9.3.1. Glepaglutide / ZP1848
14.9.3.2. INN-202 / Larazotide
14.10. Endocrine Diseases
14.10.1. Value Creation Analysis
14.10.2. Sales Forecast for Approved Peptide Therapeutics
14.10.2.1. Parsabiv ®
14.10.2.2. Lupykins
14.10.3. Sales Forecast for Clinical Peptide Therapeutics
14.10.3.1. Difelikefalin / KORSUVA / Oral CR845
14.11. Genetic Diseases
14.11.1. Value Creation Analysis
14.11.2. Sales Forecast for Approved Peptide Therapeutics
14.11.2.1. Scenesse ®
14.11.3. Sales Forecast for Clinical Peptide Therapeutics
14.11.3.1. BMN 111 / Vosoritide
14.11.3.2. Ninlaro ®
14.11.3.3. RA101495 / Zilucoplan
14.12. Hematological Diseases
14.12.1. Value Creation Analysis
14.12.2. Sales Forecast for Clinical Peptide Therapeutics
14.12.2.1. APL-2 / Pegcetacoplan
14.13. Infectious Diseases
14.13.1. Value Creation Analysis
14.13.2. Sales Forecast for Approved Peptide Therapeutics
14.13.2.1. Solnatide
14.13.3. Sales Forecast for Clinical Peptide Therapeutics
14.13.3.1. Aikening / Albuvirtide
14.13.3.2. Reltecimod
14.14. Inflammatory Diseases
14.14.1. Value Creation Analysis
14.14.2. Sales Forecast for Clinical Peptide Therapeutics
14.14.2.1. Lupuzor
14.15. Metabolic Diseases
14.15.1. Value Creation Analysis
14.15.2. Sales Forecast for Approved Peptide Therapeutics
14.15.2.1. Adlyxin ®
14.15.2.2. Trulicity ®
14.15.2.3. Mycapssa ®
14.15.2.4. Rybelsus ®
14.15.2.5. Ozempic ®
14.15.2.6. Sandostatin ®
14.15.2.7. Imcivree ™
14.15.2.8. Tanzeum ®
14.15.2.9. Tresiba ®
14.15.3. Sales Forecast for Clinical Peptide Therapeutics
14.15.3.1. Dasiglucagon
14.15.3.2. Granexin
14.15.3.3. Imcivree ™
14.15.3.4. Ozempic
14.15.3.5. Relamorelin
14.15.3.6. Tirzepatide / LY3298176
14.16. Oncological Diseases
14.16.1. Value Creation Analysis
14.16.2. Sales Forecast for Approved Peptide Therapeutics
14.16.2.1. Aplidin ®
14.16.2.2. Lupron ®
14.16.2.3. Lutathera ®
14.16.2.4. Ninlaro ®
14.16.3. Sales Forecast for Clinical Peptide Therapeutics
14.16.3.1. Balixafortide / POL6326
14.16.3.2. BL-8040 / Motixafortide
14.16.3.3. Dusquetide / SGX942
14.17. Ophthalmic Diseases
14.17.1. Value Creation Analysis
14.17.2. Sales Forecast for Clinical Peptide Therapeutics
14.17.2.1. APL-2 / Pegcetacoplan
14.17.2.2. GBT-201 / RGN-259
14.17.2.3. XG-102
14.18. Respiratory Diseases
14.18.1. Value Creation Analysis
14.18.2. Sales Forecast for Approved Peptide Therapeutics
14.18.2.1. Solnatide
14.19. Other Diseases
14.19.1. Value Creation Analysis
14.19.2. Sales Forecast for Approved Peptide Therapeutics
14.19.2.1. Lupron ®
14.19.2.2. Vyleesi ™
14.19.2.3. Xylentra ™
14.19.3. Sales Forecast for Clinical Peptide Therapeutics
14.19.3.1. BP-101
14.19.3.2. Granexin
14.19.3.3. Ensereptide / PXL01
15. CONCLUDING REMARKS
15.1. Chapter Overview
16. APPENDIX I: LIST OF APPROVED PEPTIDE THERAPEUTICS (2000-2012)
17. APPENDIX II: TABULATED DATA
18. APPENDIX III: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Peptide Modification Techniques
Figure 3.2 Historical Timeline of Peptide Therapeutics
Figure 4.1 Peptide Therapeutics: Distribution by Phase of Development
Figure 4.2 Peptide Therapeutics: Distribution by Type of Peptide
Figure 4.3 Peptide Therapeutics: Distribution by Route of Administration
Figure 4.4 Peptide Therapeutics: Distribution by Phase of Development and Route of Administration
Figure 4.5 Peptide Therapeutics: Distribution by Therapeutic Area
Figure 4.6 Peptide Therapeutics: Distribution by Phase of Development and Therapeutic Area
Figure 4.7 Peptide Therapeutics: Distribution by Route of Administration and Therapeutic Area
Figure 4.8 Grid Representation: Distribution by Phase of Development, Route of Administration and Therapeutic Area
Figure 5.1 Peptide Therapeutics Developers: Distribution by Year of Establishment
Figure 5.2 Peptide Therapeutics Developers: Distribution by Company Size
Figure 5.3 Peptide Therapeutics Developers: Distribution by Geography
Figure 5.4 Logo Landscape: Distribution of Peptide Therapeutics Developers by Phase of Development and Geography
Figure 5.5 Peptide Therapeutics Developers: Key Players
Figure 5.6 Peptide Therapeutics Developers: Distribution by Key Players and Phase of Development
Figure 5.7 Heat Map Representation: Distribution by Company Size, Phase of Development and Geography
Figure 6.1 Apellis Pharmaceuticals: Annual Revenues, 2015-2020 (USD Million)
Figure 6.2 BioLineRx: Annual Revenues, 2015-2020 (USD Million)
Figure 6.3 Eli Lilly: Annual Revenues, 2015-2020 (USD Million)
Figure 6.4 FirstString Research: Annual Revenues, 2015-2020 (USD Million)
Figure 6.5 Novo Nordisk: Annual Revenues, 2015-2020 (DKK Million)
Figure 6.6 Palatin Technologies: Annual Revenues, 2015-2020 (USD Million)
Figure 6.7 RegeneRx Biopharmaceuticals: Annual Revenues, 2015-2020 (USD Million)
Figure 6.8 Stealth BioTherapeutics: Annual Revenues, 2015-2020 (USD Million)
Figure 6.9 Takeda: Annual Revenues, 2015-2020 (JPY Million)
Figure 6.10 Zealand Pharma: Annual Revenues, 2015-2020 (DKK Million)
Figure 7.1 Heat Map Analysis: Top Pharmaceutical Companies
Figure 7.2 Big Pharma Players: Distribution by Number of Amino Acids
Figure 7.3 Big Pharma Players: Distribution by Route of Administration
Figure 7.4 Big Pharma Players: Distribution by Therapeutic Area
Figure 7.5 Spider Web Analysis: Pipeline Strength
Figure 7.6 Spider Web Analysis: Partnerships and Collaborations
Figure 7.7 Spider Web Analysis: Funding and Investments
Figure 7.8 Spider Web Analysis: Clinical Trials
Figure 7.9 Spider Web Analysis: Novo Nordisk
Figure 7.10 Spider Web Analysis: Amgen
Figure 7.11 Spider Web Analysis: Takeda
Figure 7.12 Spider Web Analysis: Eli Lilly
Figure 7.13 Spider Web Analysis: Johnson and Johnson
Figure 7.14 Harvey Ball Analysis: Big Pharma Investment Summary
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Peptide
Figure 8.5 Partnerships and Collaborations: Distribution by Route of Administration
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Partnership and Route of Administration
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership, Route of Administration and Type of Peptide
Figure 8.8 Partnerships and Collaborations: Distribution by Phase of Development
Figure 8.9 Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development
Figure 8.10 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.11 Grid Representation: Distribution by Year, Type of Partnership and Therapeutic Area
Figure 8.12 Most Active Players: Distribution by Number of Partnerships
Figure 8.13 Partnerships and Collaborations: Intracontinental and IntercontinentalAgreements
Figure 8.14 Partnerships and Collaborations: Local and International Agreements
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances, 2015-2021
Figure 9.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2015-2021 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2015-2021
Figure 9.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2015-2021 (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2015-2021 (USD Million)
Figure 9.6 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, 2015-2021 (USD Million)
Figure 9.7 Funding and Investment Analysis: Summary of Investments, 2015-2021 (USD Million)
Figure 9.8 Funding and Investment Analysis: Distribution by Geography
Figure 9.9 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 9.10 Most Active Players: Distribution by Number of Funding Instances
Figure 9.11 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 9.12 Funding and Investment Analysis: Distribution by Types of Investors
Figure 9.13 Funding and Investment Analysis: Distribution of Instances by Phase of Development
Figure 9.14 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 10.1 Clinical Trial Analysis: Scope and Methodology
Figure 10.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year,Pre 2000-2021
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Figure 10.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by TrialRegistration Year, Pre 2000-2021
Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.9 Most Active Players: Distribution by Number of Registered Trials
Figure 10.10 Clinical Trial Analysis: Emerging Focus Area
Figure 10.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 10.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 11.1 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Autoimmune Diseases
Figure 11.2 Clinical and Commercial Attractiveness Analysis of Phase III Molecules:Cardiovascular Diseases
Figure 11.3 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: CNSDiseases
Figure 11.4 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Digestive and Gastrointestinal Diseases
Figure 11.5 Clinical and Commercial Attractiveness Analysis of Phase III Molecules:Endocrine Diseases
Figure 11.6 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: GeneticDiseases
Figure 11.7 Clinical and Commercial Attractiveness Analysis of Phase III Molecules:Hematological Diseases
Figure 11.8 Clinical and Commercial Attractiveness Analysis of Phase III Molecules:Infectious Diseases
Figure 11.9 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Inflammatory Diseases
Figure 11.10 Clinical and Commercial Attractiveness Analysis of Phase III Molecules:Metabolic Diseases
Figure 11.11 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Oncological Diseases
Figure 11.12 Clinical and Commercial Attractiveness Analysis of Phase III Molecules:Ophthalmic Diseases
Figure 11.13 Clinical and Commercial Attractiveness Analysis: Phase III Molecules for OtherDiseases
Figure 14.1 Global Peptide Therapeutics Market, 2021-2030 (USD Billion)
Figure 14.2 Peptide Therapeutics Market: Distribution by Type of Peptide, 2021-2030
Figure 14.3 Peptide Therapeutics Market: Distribution by Route of Administration, 2021-2030
Figure 14.4 Peptide Therapeutics Market: Distribution by Geography, 2021-2030
Figure 14.5 Peptide Therapeutics Market: Distribution by Key Therapeutic Area, 2021-2030
Figure 14.6 Peptide Therapeutics Market for Autoimmune Diseases, 2021-2030 (USD Billion)
Figure 14.7 Peptide Therapeutics Market for Cardiovascular Diseases, 2021-2030 (USD Billion)
Figure 14.8 Peptide Therapeutics Market for CNS Diseases, 2021-2030 (USD Billion)
Figure 14.9 Peptide Therapeutics Market for Dermatological Diseases, 2021-2030 (USD Billion)
Figure 14.10 Peptide Therapeutics Market for Digestive and Gastrointestinal Diseases, 2021-2030 (USD Billion)
Figure 14.11 Peptide Therapeutics Market for Endocrine Diseases, 2021-2030 (USD Billion)
Figure 14.12 Peptide Therapeutics Market for Genetic Diseases, 2021-2030 (USD Billion)
Figure 14.13 Peptide Therapeutics Market for Hematological Diseases, 2021-2030 (USDBillion)
Figure 14.14 Peptide Therapeutics Market for Infectious Diseases, 2021-2030 (USD Billion)
Figure 14.15 Peptide Therapeutics Market for Inflammatory Diseases, 2021-2030 (USD Billion)
Figure 14.16 Peptide Therapeutics Market for Metabolic Diseases, 2021-2030 (USD Billion)
Figure 14.17 Peptide Therapeutics Market for Oncological Diseases, 2021-2030 (USD Billion)
Figure 14.18 Peptide Therapeutics Market for Ophthalmic Diseases, 2021-2030 (USD Billion)
Figure 14.19 Peptide Therapeutics Market for Respiratory Diseases, 2021-2030 (USD Billion)
Figure 14.20 Peptide Therapeutics Market for Other Diseases, 2021-2030 (USD Billion)
Table 4.1 Peptide Therapeutics: Development Pipeline
Table 5.1 Peptide Therapeutics: List of Drug Developers
Table 6.1 Apellis Pharmaceuticals: Key Highlights
Table 6.2 Apellis Pharmaceuticals: Peptide-based Drugs Portfolio
Table 6.3 Apellis Pharmaceuticals: Recent Developments and Future Outlook
Table 6.4 BioLineRx: Key Highlights
Table 6.5 BioLineRx: Peptide-based Drugs Portfolio
Table 6.6 BioLineRx: Recent Developments and Future Outlook
Table 6.7 Eli Lilly: Key Highlights
Table 6.8 Eli Lilly: Peptide-based Drugs Portfolio
Table 6.9 Eli Lilly: Recent Developments and Future Outlook
Table 6.10 FirstString Research: Key Highlights
Table 6.11 FirstString Research: Peptide-based Drugs Portfolio
Table 6.12 FirstString Research: Recent Developments and Future Outlook
Table 6.13 Novo Nordisk: Key Highlights
Table 6.14 Novo Nordisk: Peptide-based Drugs Portfolio
Table 6.15 Novo Nordisk: Recent Developments and Future Outlook
Table 6.16 Palatin Technologies: Key Highlights
Table 6.17 Palatin Technologies: Peptide-based Drugs Portfolio
Table 6.18 Palatin Technologies: Recent Developments and Future Outlook
Table 6.19 RegeneRx Biopharmaceuticals: Key Highlights
Table 6.20 RegeneRx Biopharmaceuticals: Peptide-based Drugs Portfolio
Table 6.21 RegeneRx Biopharmaceuticals: Recent Developments and Future Outlook
Table 6.22 Stealth BioTherapeutics: Key Highlights
Table 6.23 Stealth BioTherapeutics: Peptide-based Drugs Portfolio
Table 6.24 Stealth BioTherapeutics: Recent Developments and Future Outlook
Table 6.25 Takeda: Key Highlights
Table 6.26 Takeda: Peptide-based Drugs Portfolio
Table 6.27 Takeda: Recent Developments and Future Outlook
Table 6.28 Zealand Pharma: Key Highlights
Table 6.29 Zealand Pharma: Peptide-based Drugs Portfolio
Table 6.30 Zealand Pharma: Recent Developments and Future Outlook
Table 7.1 Big Pharma Players: List of Peptide Therapeutics Focused Initiatives
Table 8.1 Peptide Therapeutics: List of Partnerships and Collaborations, 2015-2021
Table 9.1 Peptide Therapeutics: List of Funding and Investments, 2015-2021
Table 12.1 Peptides and Macrocycle Drug Discovery: List of Service Providers
Table 12.2 Peptides and Macrocycle Drug Discovery Platform Providers: Information on Types of Peptide Discovered
Table 12.3 Peptide Therapeutics: List of Contract Peptide API Manufacturers
Table 12.4 Peptide Therapeutics: List of Custom Peptide Manufacturers
Table 13.1 Peptide Therapeutics: List of Novel Peptide Therapeutics
Table 14.1 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Autoimmune Diseases
Table 14.2 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Cardiovascular Diseases
Table 14.3 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for CNS Diseases
Table 14.4 Value Creation Analysis: Information on Approved Peptide Therapeutics for Dermatological Diseases
Table 14.5 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Digestive and Gastrointestinal Diseases
Table 14.6 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Endocrine Diseases
Table 14.7 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Genetic Diseases
Table 14.8 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Hematological Diseases
Table 14.9 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Infectious Diseases Infectious Diseases
Table 14.10 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics for Inflammatory Diseases
Table 14.11 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Metabolic Diseases
Table 14.12 Value Creation Analysis: Information on Approved and Clinical Stage Peptide Therapeutics for Oncological Diseases
Table 14.13 Value Creation Analysis: Information on Clinical Stage Peptide Therapeutics forOphthalmic Diseases
Table 14.14 Value Creation Analysis: Information on Approved Peptide Therapeutics for Respiratory Diseases
Table 14.15 Value Creation Analysis: Information on Approved and Clinical Stage PeptideTherapeutics for Other Diseases
Table 17.1 Peptide Therapeutics: Distribution by Phase of Development
Table 17.2 Peptide Therapeutics: Distribution by Type of Peptide
Table 17.3 Peptide Therapeutics: Distribution by Route of Administration
Table 17.4 Peptide Therapeutics: Distribution by Phase of Development and Route of
Administration
Table 17.5 Peptide Therapeutics: Distribution by Therapeutic Area
Table 17.6 Peptide Therapeutics: Distribution by Phase of Development and Therapeutic Area
Table 17.7 Peptide Therapeutics: Distribution by Route of Administration and Therapeutic Area
Table 17.8 Peptide Therapeutics Developers: Distribution by Year of Establishment
Table 17.9 Peptide Therapeutics Developers: Distribution by Company Size
Table 17.10 Peptide Therapeutics Developers: Distribution by Geography
Table 17.11 Peptide Therapeutics Developers: Key Players
Table 17.12 Peptide Therapeutics Developers: Distribution by Key Players and Phase ofDevelopment
Table 17.13 Apellis Pharmaceuticals: Annual Revenues, 2015-2020 (USD Million)
Table 17.14 BioLineRx: Annual Revenues, 2015-2020 (USD Million)
Table 17.15 Eli Lilly: Annual Revenues, 2015-2020 (USD Million)
Table 17.16 FirstString Research: Annual Revenues, 2015-2020 (USD Million)
Table 17.17 Novo Nordisk: Annual Revenues, 2015-2020 (DKK Million)
Table 17.18 Palatin Technologies: Annual Revenues, 2015-2020 (USD Million)
Table 17.19 RegeneRx Biopharmaceuticals: Annual Revenues, 2015-2020 (USD Million)
Table 17.20 Stealth BioTherapeutics: Annual Revenues, 2015-2020 (USD Million)
Table 17.21 Takeda: Annual Revenues, 2015-2020 (JPY Million)
Table 17.22 Zealand Pharma: Annual Revenues, 2015-2020 (DKK Million)
Table 17.23 Partnerships and Collaborations: Distribution by Year of Partnership
Table 17.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 17.26 Partnerships and Collaborations: Distribution by Type of Peptide
Table 17.27 Partnerships and Collaborations: Distribution by Route of Administration
Table 17.28 Partnerships and Collaborations: Distribution by Type of Partnership and Routeof Administration
Table 17.29 Partnerships and Collaborations: Distribution by Type of Partnership, Route ofAdministration and Type of Peptide
Table 17.30 Partnerships and Collaborations: Distribution by Phase of Development
Table 17.31 Partnerships and Collaborations: Distribution by Type of Partnership and Phaseof Development
Table 17.32 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.33 Most Active Players: Distribution by Number of Partnerships
Table 17.34 Partnerships and Collaborations: Intracontinental and IntercontinentalAgreements
Table 17.35 Partnerships and Collaborations: Local and International Agreements
Table 17.36 Funding and Investment Analysis: Cumulative Year-wise Distribution byNumber of Instances, 2015-2021
Table 17.37 Funding and Investment Analysis: Cumulative Year-wise Distribution of AmountInvested, 2015-2021 (USD Million)
Table 17.38 Funding and Investment Analysis: Distribution of Instances by Type of Funding,2015-2021
Table 17.39 Funding and Investment Analysis: Distribution of Total Amount Invested byType of Funding, 2015-2021 (USD Million)
Table 17.40 Funding and Investment Analysis: Distribution by Year and Type of Funding,2015-2021 (USD Million)
Table 17.41 Funding and Investment Analysis: Distribution by Year, Type of Funding andAmount Invested, 2015-2021 (USD Million)
Table 17.42 Funding and Investment Analysis: Summary of Investments, 2015-2021 (USDMillion)
Table 17.43 Funding and Investment Analysis: Distribution by Geography
Table 17.44 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 17.45 Most Active Players: Distribution by Number of Funding Instances
Table 17.46 Most Active Players: Distribution by Amount Invested (USD Million)
Table 17.47 Funding and Investment Analysis: Distribution by Types of Investors
Table 17.48 Funding and Investment Analysis: Distribution of Instances by Phase ofDevelopment
Table 17.49 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 17.50 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year,Pre 2000-2021
Table 17.51 Clinical Trial Analysis: Distribution by Trial Status
Table 17.52 Clinical Trial Analysis: Distribution by Trial Phase
Table 17.53 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Table 17.54 Clinical Trial Analysis: Distribution of Enrolled Patient Population by TrialRegistration Year, Pre 2000-2021
Table 17.55 Clinical Trial Analysis: Distribution by Study Design
Table 17.56 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.57 Most Active Players: Distribution by Number of Registered Trials
Table 17.58 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 17.59 Clinical Trial Analysis: Geographical Distribution by Number of Registered
Table 17.60 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 17.61 Global Peptide Therapeutics Market, 2021-2030 (USD Billion)
Table 17.62 Peptide Therapeutics Market: Distribution by Type of Peptide, 2021-2030
Table 17.63 Peptide Therapeutics Market: Distribution by Route of Administration, 2021-2030
Table 17.64 Peptide Therapeutics Market: Distribution by Geography, 2021-2030
Table 17.65 Peptide Therapeutics Market: Distribution by Therapeutic Area, 2021-2030
Table 17.66 Peptide Therapeutics Market for Autoimmune Diseases, 2021-2030 (USDBillion)
Table 17.67 Peptide Therapeutics Market for Cardiovascular Diseases, 2021-2030 (USDBillion)
Table 17.68 Peptide Therapeutics Market for CNS Diseases, 2021-2030 (USD Billion)
Table 17.69 Peptide Therapeutics Market for Dermatological Diseases, 2021-2030 (USDBillion)
Table 17.70 Peptide Therapeutics Market for Digestive and Gastrointestinal Diseases, 2021-2030 (USD Billion)
Table 17.71 Peptide Therapeutics Market for Endocrine Diseases, 2021-2030 (USD Billion)
Table 17.72 Peptide Therapeutics Market for Genetic Diseases, 2021-2030 (USD Billion)
Table 17.73 Peptide Therapeutics Market for Hematological Diseases, 2021-2030 (USDBillion)
Table 17.74 Peptide Therapeutics Market for Infectious Diseases, 2021-2030 (USD Billion)
Table 17.75 Peptide Therapeutics Market for Inflammatory Diseases, 2021-2030 (USDBillion)
Table 17.76 Peptide Therapeutics Market for Metabolic Diseases, 2021-2030 (USD Billion)
Table 17.77 Peptide Therapeutics Market for Oncological Diseases, 2021-2030 (USD Billion)
Table 17.78 Peptide Therapeutics Market for Ophthalmic Diseases, 2021-2030 (USD Billion)
Table 17.79 Peptide Therapeutics Market for Respiratory Diseases, 2021-2030 (USD Billion)
Table 17.80 Peptide Therapeutics Market for Other Diseases, 2021-2030 (USD Billion)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES